A Study of the Effectiveness of Moderna COVID-19 Vaccine

Launched by MODERNATX, INC. · Jul 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of the Moderna COVID-19 vaccine in preventing COVID-19 infections and severe cases of the disease. Researchers at Kaiser Permanente Southern California are looking at how well the vaccine works in the real world, meaning they want to see how effective it is in a diverse group of people who have received the vaccine. They will track participants to see if they test positive for the virus or experience severe illness, like hospitalization or death, related to COVID-19.

To be eligible for this study, participants need to be at least 18 years old and a member of Kaiser Permanente for at least a year before the study starts. They should not have received any COVID-19 vaccine other than the Moderna vaccine. Participants will not need to do anything special for the study; their health will be monitored as part of routine care. This study is currently active but not recruiting new participants, meaning they are not looking for more people to join right now.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥18 years at index date (participants aged 6 months through 17 years will also be included after Food and Drug Administration \[FDA\] authorization to vaccinate younger age groups)
• • KPSC member for ≥12 months prior to index date through 14 days after the index date (allowing a 31-day gap)
• Exclusion Criteria:
• • Receipt of a COVID-19 vaccine other than Moderna COVID-19 vaccine prior to or on the index date
• • Receipt of 2 doses of Moderna COVID-19 vaccine \<24 days apart for 2-dose exposed cohort
• • Receipt of any COVID-19 vaccine \<14 days after the index date
• • No health care utilization and no vaccination from the 2 years prior to the index date through the index date
• • Occurrence of a COVID-19 outcome \<14 days after the index date